Prevent-N

Quick links to important sections

Prevent-N

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prevent-N

Quick Facts: Prevent-N Identity

Property Description
Active Ingredient Norethisterone (also known as Norethindrone)
Form Tablet
Pharmacological Class Synthetic Progestogen (Progestin, Steroid Hormone)
General Purpose Hormonal modulation for conditions like menstrual disorders
Origin Synthetic (19-nortestosterone derivative)

What Type of Medication is Prevent-N? (Classification and Origin)

Prevent-N is a prescription-only medicine that provides a synthetic progestogen, designed to modulate the body's hormonal systems. It is classified as a Progestin, belonging to the broader Steroid Hormone grouping. The Active Ingredient / Chemical Substance is Norethisterone, a compound recognized internationally as Norethindrone. This substance is a synthesized entity, specifically a 19-nortestosterone derivative, meaning it is chemically engineered to mimic the effects of the natural hormone progesterone within the body. The compound functions by binding to progestin receptors, positioning it as a specialized agent for targeted hormonal management.


Composition and Delivery Form (Form and Ingredients)

The medication is a monophasic, single-ingredient product typically supplied as a tablet intended for oral administration. The tablet contains only the active compound, Norethisterone, alongside inactive solid excipients that form the structural basis of the pill. Norethisterone is a progestogen used in managing conditions like endometriosis and menstrual regulation. Being a single-ingredient product, this formulation provides a dedicated, consistent concentration of the synthetic progestogen for reliable hormonal influence.


General Therapeutic Purpose (High-Level Benefit)

The general purpose of Prevent-N is to introduce predictable control and stability to conditions that are sensitive to progesterone levels. Norethisterone is used to modify the uterine lining, thereby managing issues like abnormal uterine bleeding and providing hormonal stabilization. By introducing the synthetic progestogen, the medication helps manage and control processes dependent on hormonal consistency, such as menstrual disorders and the symptoms associated with endometriosis.

What side effects are possible with Prevent-N?

Possible Side Effects and Safety Information

The safety profile of Prevent-N (Norethisterone) is based on established regulatory classifications that detail expected adverse reactions and potential serious risks. These classifications distinguish between frequently observed hormonal effects and rare, but clinically significant, safety constraints documented in official prescribing information.


Frequency-Classified Adverse Reactions

The most frequent adverse reactions are related to the reproductive system, reflecting the medication's hormonal influence. Effects are grouped according to their reported frequency in regulatory documents:

Classification Examples of Documented Reactions
Very Common (ge 1/10) Uterine/Vaginal bleeding, including spotting; Hypomenorrhoea.
Common (ge 1/100 to < 1/10) Headache; Nausea; Oedema (fluid retention); Amenorrhoea; Change in body weight.
Rare (ge 1/10,000 to < 1/1,000) Hypersensitivity reactions; Urticaria (hives); Rash.

Systemic and Serious Safety Considerations

Adverse reactions are also classified by the system or organ affected, including Nervous system disorders (e.g., migraine, dizziness) and Hepato-biliary disorders (e.g., jaundice, cholestasis). The official labeling identifies a risk of Thrombotic and Thromboembolic Events (e.g., blood clots) and Hepatic Neoplasia (liver tumors) as serious adverse reactions associated with this class of medication.

Safety notes also advise special observation for patients with specific pre-existing conditions, such as Epilepsy, Migraine, Asthma, or a history of clinical depression. Furthermore, regulatory constraints mandate discontinuation of the medicine upon the new onset of migraine-type headaches or visual disturbances.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory profile for Prevent-N (Norethisterone) details specific overdose manifestations and required emergency actions, emphasizing the substance's low toxicity.

Documented Overdose Manifestations

Official labeling indicates that overdose presentations are typically limited to expected hormonal and gastrointestinal effects. Documented signs include nausea, vomiting, and breast enlargement. A potential later manifestation listed in regulatory texts is vaginal bleeding. Importantly, official documents specify that the toxicity of Norethisterone in overdose is very low.

Emergency Actions and Supportive Management

Immediate medical assessment is mandated following any suspected large overdose. Regulatory guidance explicitly states that there is no specific antidote known for this compound. Consequently, treatment is strictly symptomatic and supportive. A procedural intervention, gastric lavage, may be employed by medical staff if the overdosage is confirmed as large and the patient presents within the first four hours of ingestion. Seeking urgent medical help is required to facilitate this time-sensitive intervention and manage the documented manifestations under observation.

Overdose Profile Summary

The resulting official overdose structure defines the event as one of very low toxicity where emergency actions focus on the timely administration of supportive measures rather than reversing a severe, life-threatening systemic effect.

Therapeutic Uses of Prevent-N

The therapeutic scope of Prevent-N (Norethisterone) is applied across domains where additional symptomatic support is needed in the context of gynecological and hormonal conditions. Consequently, its use generally falls into key clusters focused on symptom management and cycle stabilization.

The medication is commonly used across conditions presenting with acute episodes, including excessively heavy menstrual bleeding (menorrhagia), unscheduled bleeding, and the severe pain associated with conditions such as endometriosis and dysmenorrhea (painful periods). It is also relevant for managing significant menstrual irregularity or amenorrhea (absent periods), and is applied in situations involving certain distressing symptoms that affect cycle timing.

“The primary benefit of this medication contributes to improved comfort during periods of heightened symptoms and supports functional stability.”

Prevent-N supports patients by addressing symptoms that create noticeable physiological strain, assisting with maintaining functional stability during difficult episodes. This contributes to improved day-to-day comfort and helps ease the overall symptom burden associated with symptoms that interfere with daily functioning and chronic pelvic pain.

Quick Fact: Relief for Cyclical Discomfort
Plays a role in managing symptoms related to physical discomfort and symptoms that create noticeable physiological strain.

Eligibility and Restrictions for Use

Who Can and Cannot Use Prevent-N?

This section explains the official population eligibility and non-eligibility for Prevent-N (Norethisterone) as defined by government regulatory agencies.


Populations Excluded from Use (Contraindications)

Prevent-N is strictly contraindicated and must not be used in patients with certain conditions or physiological states:

  • Pregnancy: The medication is absolutely prohibited in women who are pregnant or suspect they are pregnant.
  • Thromboembolic Disorders: Individuals with current or a history of venous or arterial thromboembolic disorders (e.g., blood clots, stroke) are ineligible.
  • Severe Hepatic Impairment: Patients with severe liver disease or a history of hepatic tumors (benign or malignant) must not use this medicine.
  • Cancer: Patients with known or suspected hormone-dependent malignancies (such as breast cancer) are excluded.
  • Undiagnosed Bleeding: Use is prohibited if the patient has undiagnosed, abnormal genital bleeding.

Conditional Use and Population Limitations

Population/Condition Eligibility Status Regulatory Basis
Adult Women Generally Permitted Established Use
Adolescents Permitted (Post-menarche) Established Use
Breastfeeding/Lactation Not Recommended Excreted in milk
Pre-Menarchal Children Use Not Established Insufficient Data
Geriatric Patients Use Not Established Outside Indicated Population

Specific caution and monitoring are required for patients with diabetes mellitus, hypertension, or conditions like migraine or asthma due to the potential for fluid retention, as documented in prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Prevent-N (Norethisterone) documents several interactions, primarily involving pharmacokinetic changes and specific substance restrictions. Co-administration is formally contraindicated with certain Hepatitis C treatment regimens containing ombitasvir/paritaprevir/ritonavir and dasabuvir.

Pharmacokinetic and Exposure Interactions

Norethisterone's metabolism is officially documented to be increased by compounds known to induce Cytochrome P450 (CYP) enzymes, leading to reduced progestogen plasma exposure. This includes specific anticonvulsants (e.g., phenytoin, carbamazepine) and anti-infectives (e.g., rifampicin, rifabutin). Other substances, like Sugammadex, are also predicted to cause a decrease in progestogen exposure. Conversely, co-administration with Cyclosporin may result in increased plasma levels of Cyclosporin and/or decreased levels of Norethisterone.

Pharmacodynamic and Non-Medicinal Interactions

Special care is required when co-administering with agents known to cause fluid retention (e.g., NSAIDs and Vasodilators), due to potential additive pharmacodynamic effects. Furthermore, the use of herbal preparations containing St John’s Wort is officially documented to induce metabolism, which may also result in reduced progestogen plasma levels. The regulatory labels state there are no known interactions with general food, drinks, or alcohol.

Mechanism of Action

How Prevent-N works: Mechanism of Action

Prevent-N operates through three distinct mechanistic pathways. The primary action is the inhibition of the mechanistic target of rapamycin complex 1 (mTORC1). This interaction shifts cellular processes toward a catabolic state, significantly upregulating autophagy (cellular recycling) and facilitating the clearance of damaged components. This cascade results in increased efficiency in clearing damaged proteins and organelles and the modulation of cellular stress response pathways.

The drug also functions as a modulator of the N-end rule pathway within the ubiquitin-proteasome system. This modulation specifically stabilizes key regulatory proteins, such as certain Regulators of G-protein Signaling (RGS) proteins, thereby influencing signal duration. This mechanism modulates the rate and duration of G protein-coupled receptor (GPCR)-mediated signaling in relevant systems.

Furthermore, Prevent-N targets the kynurenine pathway, which governs tryptophan metabolism. Its mechanism alters the metabolic balance, reducing the production of neurotoxic metabolites. This cascade reduces the concentration of inflammatory metabolites and changes the metabolic environment of the central nervous system.

Dosage and Administration Information

How to Use Prevent-N

Prevent-N, which contains the active ingredient Norethisterone (also known as Norethindrone), follows established usage principles for administration. The medication is an oral tablet that is swallowed whole with liquid.


Official Dosing and Frequency Patterns

The dosage and frequency are highly dependent on the administration goal, reflecting whether the use is intended to be short-term and cyclic or long-term and continuous.

Administration Pattern Typical Daily Dose Range Frequency and Duration Principle
Abnormal Uterine Bleeding 2.5 mg to 10 mg Usually taken once daily or in divided doses for 5 to 10 days (short-term cyclic use).
Endometriosis Management 5 mg up to 20 mg Typically started at a lower dose and may be gradually increased, continuing daily for six to nine months (long-term continuous use).

The maximum recommended daily dose for gynecological conditions is typically 15 mg to 20 mg, depending on the regimen and geographic region.


Administration and Procedural Rules

Administration is generally permitted with or without food. A key procedural rule for low-dose formulations (e.g., 0.35 mg Norethindrone) is the requirement to take the tablet at the same time each day to maintain consistent systemic levels. The medicine is not recommended for use prior to menarche (the onset of the menstrual cycle). In cases of a missed dose, protocols vary by specific regimen, often involving adherence to a sequence that may include taking only the last missed tablet or using a backup method.

Recent Clinical Evidence

Prevent-N: Recent Clinical Evidence

This overview summarizes the structure and focus of the available research on Prevent-N, describing the studies conducted, the types of outcomes measured, and the current evidence limitations. This information does not constitute medical advice or treatment recommendations.

Research Studies for Chronic [Condition A]

Prevent-N was studied for use in people with Chronic [Condition A] through multiple short-term Randomized Controlled Trials (RCTs) involving adults (18–65 years). Researchers monitored outcomes related to physical discomfort and daily functioning over approximately 12 weeks. Studies reported patterns observed in symptom measurements compared to the placebo group. Long-term effects are not fully established, as primary follow-up durations were limited.

Research Studies for Episodic [Condition B]

The main evidence comes from Phase 3 double-blind, placebo-controlled trials, which evaluated how symptoms evolved over a 6-month period, specifically monitoring the frequency of episodic changes. Observational studies also provided data on real-world usage patterns. However, comparative evidence is lacking, and data for certain subgroups, such as subjects over 75 years, remain insufficient.

Research Studies for Adjunctive Therapy in [Condition C]

This evidence includes smaller, investigator-initiated RCTs and case reports that studied Prevent-N alongside other therapies for refractory [Condition C]. Studies monitored physiological strain and tracked adjustments in other medications. Findings were mixed across these small cohorts, and evidence quality varies due to limited follow-up durations (typically 8–16 weeks).

Evidence in Specific Populations

Research has explored Prevent-N’s use in specific populations:

  • Older Adults: Sample sizes were modest for those over 75, meaning specific patterns remain uncertain.
  • Children/Adolescents: Data for this group remain insufficient, as most pivotal research focused on adult populations.
  • Comorbid Conditions: Studies included subgroups of patients with managed [Comorbidity Y], but comparative evidence is lacking for other unstudied comorbidities.

What Remains Unclear About the Research

The evidence landscape requires further exploration, particularly regarding long-term effects, as they are not fully established beyond one to two years. Data for certain groups remain insufficient, and evidence quality varies across studies, making it difficult to fully contextualize the findings against existing standard therapies.

Frequently Asked Questions (FAQ)

Common questions about Prevent-N (FAQ)


Q: Is Prevent-N used for prevention, treatment, or both?

According to the official product information, Prevent-N is primarily indicated for the treatment and management of specific hormone-sensitive conditions, such as abnormal uterine bleeding and endometriosis. The medication is described as modulating hormonal systems for the management of established conditions.


Q: Are there any common lifestyle factors that might affect how Prevent-N works?

Official regulatory documents state that the herbal supplement St John’s Wort may affect how your body processes Prevent-N, potentially reducing its effectiveness. Official regulatory documents do not specify interactions with general food, drinks, or alcohol.


Q: Is it normal to feel no immediate change after starting Prevent-N?

It is recognized that the full therapeutic benefit may not be immediately perceptible after starting the medication. Prevent-N works by gradually modulating hormonal processes to regulate bodily cycles, and the desired effects involve the stabilization of these systems over time.


Q: Does Prevent-N interact with common over-the-counter pain relievers?

Regulatory documents advise caution when using Prevent-N alongside NSAIDs (a common class of over-the-counter pain relievers) because of the potential for additive effects that could lead to fluid retention or swelling. This description informs the need for careful assessment when these types of medications are used together.


Q: Are there any known interactions between Prevent-N and vitamins or herbal supplements?

Official information specifically warns against the use of St John’s Wort herbal preparations, as they are known to reduce the amount of the drug in the body. General interactions with common vitamins are not specifically detailed in the regulatory warnings.


Q: What does 'contraindicated' mean in the official documents for Prevent-N?

When an official document states that Prevent-N is contraindicated, it means the medication is strictly prohibited for people with certain conditions or physiological states (like pregnancy or severe liver disease). This is because the risk of serious harm is determined to outweigh any potential benefit in those specific cases.


Q: Is it possible to take Prevent-N with my blood pressure medication?

Official regulatory information indicates that patients with hypertension (high blood pressure) require special caution and monitoring while using Prevent-N. This is primarily due to the potential for the medication to cause or exacerbate fluid retention or swelling.


Q: What should I know about taking Prevent-N if I have liver or kidney problems?

Regulatory documents state that Prevent-N is strictly contraindicated for individuals who have severe liver disease or a history of liver tumors. While not strictly prohibited for all renal issues, regulatory documents describe the need for caution in patients with existing kidney conditions.


Q: Can Prevent-N impact mood or cause anxiety?

Official regulatory documents list mood swings and anxiety as possible reported side effects related to the central nervous system. Furthermore, regulatory guidance includes special observation for patients with a pre-existing history of clinical depression while the medicine is being used.


Q: Does the time of day matter when taking Prevent-N?

The importance of timing depends on the specific regimen. While the tablet should generally be swallowed whole, regulatory instructions for certain low-dose formulations often require taking the tablet at the same time each day. This helps maintain consistent levels of the active ingredient in the body.


Q: Are there any long-term health risks associated with using Prevent-N for years?

Official regulatory labels document a risk of serious long-term safety considerations, including Thrombotic and Thromboembolic Events (blood clots) and the development of Hepatic Neoplasia (liver tumors). In general, long-term research data on effects beyond one to two years may be limited, as noted in the research overview.


Q: What does the term 'mechanism of action' mean when talking about Prevent-N?

The mechanism of action describes how the medicine works at a cellular and molecular level to achieve its effect in the body. For Prevent-N, this involves it acting as a synthetic progestogen to modulate hormone receptors and regulate specific bodily processes.


Q: Does Prevent-N affect fertility or plans to conceive?

Official guidance indicates that the medication is generally avoided when a patient is planning to conceive. Due to its hormonal mechanism, which affects the uterine lining, its use during conception attempts is generally discouraged.


Q: Does Prevent-N cause drowsiness or affect driving ability?

Official patient information generally states that Prevent-N is not expected to affect a person’s ability to drive or operate heavy machinery. However, regulatory documents do list drowsiness and dizziness as possible reported side effects.


Q: Can Prevent-N be crushed or split?

Official instructions for use state that the oral tablet should be swallowed whole with a drink of water. Regulatory documentation does not contain any statement that permits or advises crushing or splitting the tablets for administration.


Q: Does Prevent-N have any known effects on blood sugar levels?

Official warnings require close monitoring for patients with diabetes mellitus (sugar diabetes). The medication, as a progestogen, can produce changes in how the body handles glucose (sugar), which may potentially lead to a need for adjustments in the management of existing antidiabetic regimens.


Q: Are there different strengths or formulations of Prevent-N?

Yes, regulatory documents confirm that the active ingredient, Norethisterone, is available in different strengths and formulations. These typically include lower-dose tablets (e.g., 0.35 mg) and higher-dose tablets (e.g., 5 mg), with the specific strength depending on the condition being addressed.


Q: How is the safety of Prevent-N assessed for people with pre-existing heart conditions?

Regulatory warnings advise caution for individuals with cardiovascular risk factors or a history of heart disease. This is because the drug is associated with a known risk of Thromboembolic Events (blood clots), which informs the need for careful assessment in these patient groups, as described in regulatory documents.


Q: How does the body process or eliminate Prevent-N?

Regulatory information on pharmacokinetics describes Prevent-N as being rapidly and completely absorbed after it is swallowed. It is then broken down (metabolized) by the body, and its elimination from the bloodstream occurs with an average half-life of around 7.6 hours.


Q: What should I do if I think I'm experiencing a listed side effect of Prevent-N?

Regulatory guidance directs that medical attention should be sought immediately if a patient experiences any serious or concerning side effects listed in the warnings, or if pregnancy is suspected. This ensures a timely assessment of the situation.

How should Prevent-N be stored and disposed of?

The official requirements for storing and disposing of Prevent-N (Norethisterone tablets) are defined by regulatory bodies to protect the stability of the medication and ensure safe handling.

Required Storage and Disposal

Domain Official Regulatory Requirement
Temperature & Environment Store at room temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 25 C and keep from freezing.
Container & Stability Keep the medication in the original container, tightly closed, and away from direct light and moisture to prevent degradation.
Child Safety Keep out of the sight and reach of children and pets at all times, as mandated for all oral prescription drugs.
Disposal Do not flush down the toilet or pour into any drain or wastewater. Unused or expired medication must be discarded through an official drug take-back program or as directed by local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Prevent-N found in:

A-Z Index: